HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price

Immunic (NASDAQ:IMUX) had its target price reduced by HC Wainwright from $10.00 to $8.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other research firms have also commented on IMUX. D. Boral Capital reduced their price target on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday. Chardan Capital began coverage on shares of Immunic in a research note on Monday, September 29th. They set a “buy” rating and a $13.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. Roth Capital initiated coverage on shares of Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 price target for the company. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immunic currently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Immunic Trading Up 9.3%

Shares of NASDAQ IMUX opened at $0.78 on Friday. Immunic has a 12-month low of $0.56 and a 12-month high of $1.42. The company has a market cap of $76.80 million, a P/E ratio of -0.83 and a beta of 1.53. The stock has a fifty day moving average price of $0.83 and a 200 day moving average price of $0.86.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. On average, sell-side analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc grew its holdings in Immunic by 678.1% during the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after acquiring an additional 7,184,457 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after purchasing an additional 219,957 shares during the last quarter. Focus Partners Wealth grew its stake in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after purchasing an additional 415,104 shares in the last quarter. 683 Capital Management LLC increased its holdings in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after buying an additional 200,000 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Immunic in the third quarter valued at about $239,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.